PREVALENCE OF ERECTILE DYSFUNCTION AFTER PELVIC RADIOTHERAPY

Authors

  • RA ANWER Department of Oncology, Nishtar Cancer Centre Nishtar Medical University and Hospital Multan, Pakistan
  • A BASHIR Department Of Radiation Oncology, Dg Khan Teaching Hospital Dg Khan, Pakistan
  • HF SHER Department Of Health Physicist, Nishtar Cancer Centre Nishtar Medical University and Hospital Multan, Pakistan
  • A MANAN Department Of Oncology, Nishtar Cancer Centre Nishtar Medical University and Hospital Multan, Pakistan
  • A AMMARA Department Of Health Physicist, Nishtar Cancer Centre Nishtar Medical University and Hospital Multan, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1467

Keywords:

Erectile Dysfunction, Pelvic Radiotherapy, Cancer Survivors, Risk Factors, Quality of Life, Pakistan

Abstract

Erectile dysfunction (ED) is a common complication among male cancer survivors undergoing pelvic radiotherapy, significantly impacting their quality of life. Despite its high prevalence globally, data on ED among Pakistani cancer survivors remain limited. Objective: To determine the prevalence, severity, and associated risk factors of ED among male patients undergoing pelvic radiotherapy at Nishtar Medical University and Hospital, Multan. Methods: This prospective observational study included 50 male patients aged 50–85 years undergoing pelvic radiotherapy for malignancies. Baseline and six-month follow-up assessments of erectile function were conducted using the International Index of Erectile Function (IIEF-5) questionnaire. Factors associated with ED, including age, comorbidities, and treatment parameters, were analyzed using SPSS version 26.Results: The prevalence of ED six months post-radiotherapy was 61%. Advanced age (≥65 years) and diabetes were significant risk factors, with 71.4% and 88.9% of patients, respectively, developing ED. Moderate and severe ED accounted for 42.9% and 35.7% of cases, respectively. Cultural stigma and limited healthcare resources were additional barriers to managing ED in the Pakistani context. Conclusion: ED is highly prevalent among male patients undergoing pelvic radiotherapy, with advanced age and diabetes being significant contributors. These findings underscore the need for routine ED screening, culturally sensitive counseling, and targeted interventions to improve the quality of life for cancer survivors in Pakistan.

Downloads

Download data is not yet available.

References

Droupy S, Alsaid B, Chevrot A, et al. Erectile dysfunction after radiotherapy for prostate cancer: A review. Int J Impot Res. 2018;30(1):11–18. doi:10.1038/s41443-017-0006-7.

Incrocci L, Slagter C, Slob AK, et al. A prospective study on erectile function after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54(1):103–108. doi:10.1016/S0360-3016(02)02809-8.

Mir AR, Nasir A, Khan SM. Age as a risk factor for erectile dysfunction post-radiotherapy. Pak J Med Sci. 2021;37(4):112–117. doi:10.12669/pjms.37.4.4112.

Ahmed A, Rehman T, Farooq A. The burden of pelvic malignancies in Pakistan: Challenges and solutions. Pak J Cancer. 2020;7(2):45–52. doi:10.15537/pjc.2020.0002.

Trost L, Mulhall JP. Impact of diabetes on erectile dysfunction and sexual health. Curr Diab Rep. 2016;16(2):13. doi:10.1007/s11892-016-0708-6.

Chung E, Brock G. Diabetes and erectile dysfunction post-radiotherapy: Implications and management. BJU Int. 2013;112(4):494–503. doi:10.1111/bju.12222.

Khan H, Ahmed S, Siddiqui M. Quality of life in Pakistani cancer survivors: The overlooked impact of sexual dysfunction. Pak J Rehabil. 2021;10(1):23–30. doi:10.3389/pjrehab.2021.1008.

Zafar S, Naveed R, Jamil A. Cultural barriers in addressing sexual health issues in Pakistani cancer patients. J Pak Med Assoc. 2022;72(5):710–715. doi:10.47391/JPMA.005.

Pinkawa M, Piroth MD, Fischedick K, et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Strahlenther Onkol. 2010;186(1):46–50. doi:10.1007/s00066-010-2108-3.

Davison BJ, So AI, Goldenberg SL. Quality of life and erectile function after pelvic radiotherapy. Oncology (Williston Park). 2007;21(10):1180–1188. PMID: 17955018.

Droupy S, Alsaid B, Chevrot A, et al. Erectile dysfunction after radiotherapy for prostate cancer: A review. Int J Impot Res. 2018;30(1):11–18. doi:10.1038/s41443-017-0006-7.

Incrocci L, Slagter C, Slob AK, et al. A prospective study on erectile function after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54(1):103–108. doi:10.1016/S0360-3016(02)02809-8.

Mir AR, Nasir A, Khan SM. Age as a risk factor for erectile dysfunction post-radiotherapy. Pak J Med Sci. 2021;37(4):112–117. doi:10.12669/pjms.37.4.4112.

Pinkawa M, Piroth MD, Fischedick K, et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Strahlenther Onkol. 2010;186(1):46–50. doi:10.1007/s00066-010-2108-3.

Trost L, Mulhall JP. Impact of diabetes on erectile dysfunction and sexual health. Curr Diab Rep. 2016;16(2):13. doi:10.1007/s11892-016-0708-6.

Chung E, Brock G. Diabetes and erectile dysfunction post-radiotherapy: Implications and management. BJU Int. 2013;112(4):494–503. doi:10.1111/bju.12222.

Davison BJ, So AI, Goldenberg SL. Quality of life and erectile function after pelvic radiotherapy. Oncology (Williston Park). 2007;21(10):1180–1188. PMID: 17955018.

Zafar S, Naveed R, Jamil A. Cultural barriers in addressing sexual health issues in Pakistani cancer patients. J Pak Med Assoc. 2022;72(5):710–715. doi:10.47391/JPMA.005.

Downloads

Published

2024-12-30

How to Cite

ANWER , R., BASHIR , A., SHER , H., MANAN , A., & AMMARA , A. (2024). PREVALENCE OF ERECTILE DYSFUNCTION AFTER PELVIC RADIOTHERAPY. Biological and Clinical Sciences Research Journal, 2024(1), 1467. https://doi.org/10.54112/bcsrj.v2024i1.1467